



## Original article

# Association between standardized uptake value and survival in patients with locally advanced or metastatic squamous cell head and neck cancer

Zeynep Oruc<sup>a, \*</sup>, M. Emin Buyukbayram<sup>b</sup>, Muhammet Ali Kaplan<sup>a</sup>, Zuhat Urakci<sup>a</sup>, Mehmet Küçüköner<sup>a</sup>, Abdurrahman Isikdogan<sup>a</sup>

<sup>a</sup> Dicle University Faculty of Medicine Department of Medical Oncology, Diyarbakır, Turkey

<sup>b</sup> Dicle University Faculty of Medicine Department of Internal Diseases, Diyarbakır, Turkey

## ARTICLE INFO

## Article history:

Received 26 October 2015

Received in revised form

30 October 2015

Accepted 9 November 2015

Available online 10 December 2015

## Keywords:

Standard uptake value

PET CT

Head and neck cancer

## ABSTRACT

**Introduction and objective:** The present study aimed to evaluate the association between tumor Standard Uptake Value (SUVmax) values obtained by PET/CT, and survival in patients with locally advanced or metastatic squamous cell head and neck cancer.

**Method:** The present study included 38 patients with locally advanced or metastatic squamous cell head and neck cancer, who were staged using PET/CT at diagnosis. PET/CT imaging findings were evaluated retrospectively. The effect of SUVmax value by PET/CT on overall survival was analyzed.

**Results:** The most common tumor localization was laryngeal cancer among 38 patients included in the study (n = 25, 65.8%). The study group consisted of mostly male patients (n = 33, 86.8%), and the median age was 58 (range: 24–77). The median SUVmax value was 11 (range: 3–58). Median survival was 32.7 months in patients with SUVmax ≤11 compared to 16.5 months in patients with SUVmax >11 (p = 0.019).

Copyright © 2015 Turkish Society of Medical Oncology. Publishing services provided by Elsevier. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

The TNM stage is the most important prognostic factor in patients with head and neck cancer. This staging system is based on imaging methods such as Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI). Conventional imaging methods remain incapable of differentiating metastatic and non-metastatic lymph nodes and identifying residual or recurrent masses due to the treatment-related changes in the tissues.<sup>1–4</sup> Positron Emission Tomography/CT (PET/CT) is commonly used to identify regional lymph node metastases, and to establish post-treatment residual tumor and loco-regional recurrence since it can metabolically display active lesions in patients with head and neck cancer.

PET/CT 2-18F-fluoro -2-deoxy-D-glucose (18F-FDG) is a useful imaging technique for pre-treatment staging, radiotherapy

planning, evaluation of treatment response, and post-treatment follow-up in head and neck cancer as it is in many cancer types. As measured by PET/CT, the standard uptake value (SUVmax value) (18F-FDG tumor uptake) is associated with vitality and proliferative activity of the tumor.<sup>5,6</sup> Therefore, a high SUVmax value may indicate tumor aggressiveness. Several retrospective studies have investigated the prognostic significance of SUVmax value. There are many studies that have suggested poorer post-treatment outcomes in patients with higher SUVmax values on PET/CT.<sup>7–9</sup> Despite several studies, the prognostic value of SUVmax value of the primary tumor is still controversial in patients with head and neck cancer. The present study aimed to evaluate the association between SUVmax value as a prognostic marker and survival in patients with head and neck cancer.

## 2. Materials and methods

The study included patients with locally advanced or metastatic squamous cell head and neck cancer receiving palliative treatment who were staged by PET/CT at the diagnosis at our clinic between January 2007 and June 2013. They had an ECOG (Eastern

\* Corresponding author. Dicle Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji Bölümü, Kıtılbil Caddesi, 21280 Diyarbakır, Turkey. Tel.: +90 412 248 80 01.

E-mail address: [zeynep44oruc@hotmail.com](mailto:zeynep44oruc@hotmail.com) (Z. Oruc).

Peer review under responsibility of Turkish Society of Medical Oncology.

Cooperative Oncology Group) performance status of 0–2. The tumor localization of the patients with head and neck cancer, ECOG performance score, tumor grade, and whether the tumor was locally advanced or metastatic were recorded initially. The patients' clinical and the tumor's pathological characteristics are presented in Table 1.

All whole-body PET/CT images were obtained using a PET/CT scanner (Biograph Six LSO; Siemens Medical Solutions) consisting of a PET scanner and a 6-section CT scanner. After ensuring that the peripheral blood glucose level was <150 mg/dL, patients received an intravenous injection of 3 MBq/kg of FDG. PET/CT scanning was performed from the center of the skull to the upper thigh 60 min after the injection and additional regional PET/CT scanning was performed. CT was performed with the following settings: 110 kV; 30 mA; tube rotation time, 0.8 s/rotation; pitch, 2; and section thickness, 2.5 mm (whole body CT had 307 or 356 slices). The PET scans were performed immediately after the CT scans in the identical transverse field of view. All 18F-FDG PET-CT images were interpreted qualitatively by 2 nuclear medicine physicians with prior knowledge of the clinical history. SUVmax within the region of interest (ROI) chosen by a nuclear medicine specialist were used as standard values.

OS (overall survival) was defined as the time from diagnosis to death. The median SUVmax value of the primary tumor was calculated. The median SUVmax value of the primary tumor was 11. The evaluated patients were analyzed for survival by classifying into two groups with SUVmax value  $\leq 11$  and SUVmax value  $> 11$ .

Statistical analysis was performed using SPSS 17.0 software. Survival was analyzed using Kaplan–Meier method and log-rank test. A univariate analysis was used to evaluate the association between age, gender, ECOG performance status, stage (locally advanced/metastatic), grade, and mortality risk. These variables were also evaluated by multivariate analysis. A p value of less than or equal to 0.05 was considered statistically significant.

### 3. Results

There were 33 (86.8%) males and five females among 38 patients included in the study. The median age was 58 (range: 24–77). The number of patients with locally advanced disease and metastatic disease was 33 (86.8%) and five (13.2%), respectively. Of 38 patients included in the study, 25 (65.8%) patients had laryngeal cancer. Of

the other 13 (34.2%) patients, eight patients had nasopharyngeal cancer, one patient had hypopharyngeal cancer, one patient had oropharyngeal cancer, one patient had nasal cancer, and one patient had salivary gland cancer. The number of patients with ECOG PS of 0–1 and ECOG PS of 2 was 26 (68.4%) and 12 (31.6%), respectively. The treatment strategies (surgery, RT, CT, CT + RT) administered to the patients were not specified separately in the study.

The univariate analysis of overall survival by tumor SUVmax, age, gender, performance score, stage, grade, and SUVmax is presented in Table 2. In the univariate analysis, median overall survival was 32.7 months in patients aged  $\leq 60$  compared to 17.6 months in patients aged  $> 60$  ( $p = 0.528$ ). Median OS was 46.2 months in female patients compared to 17.6 months in male patients ( $p = 0.439$ ). Median OS was 22.6 months in patients with ECOG performance status of 0–1 compared to 18.9 months in patients with ECOG PS  $> 1$  ( $p = 0.245$ ). Median OS was 21.4 months in patients with locally advanced disease compared to 14.2 months in metastatic patients ( $p = 0.111$ ). Median OS was 34.2 months in patients of pathological tumor grade 1 compared to 46.2 months in grade 2 patients and 18.9 months in grade 3 patients ( $p = 0.172$ ).

Median overall survival was lower in patients aged  $> 60$ , male patients, patients with lower performance, metastatic patients, and patients with higher TM grade; however, such a difference did not reach statistical significance. The median SUVmax of the primary tumor was 11 in the present study. Median overall survival was 32.7 months in patients with SUVmax  $\leq 11$  compared to 16.5 months in patients with SUVmax  $> 11$ , which was statistically significant ( $p = 0.019$ ). All survival figures established by median tumor SUVmax value and p values are presented in Fig. 1.

The multivariate analysis revealed that only the SUVmax (odds ratio 3.16, 95% CI 1.14–8.69,  $p = 0.026$ ) value is an independent prognostic marker. There was no statistical significance in age, gender, ECOG performance status, and stage variables. The multivariate analysis is summarized in Table 3.

### 4. Discussion

Recently, PET/CT has been proven to be superior to conventional staging methods such as CT and MR in the diagnosis and staging of patients with head and neck cancer. In previous studies, PET/CT

**Table 1**  
Characteristics of patients with head and neck cancer.

Characteristics	N = 38 (%)
Age (years)	58 (24–77)
Gender (M/F)	33/5 (86.8/13.2)
Tumor localization	
Oropharynx	1 (2.6)
Hypopharynx	2 (5.3)
Nasopharynx	8 (21)
Larynx	25 (65.8)
Nasal	1 (2.6)
Salivary gland	1 (2.6)
TNM	
Locally advanced	33 (86.8)
Metastatic	5 (13.2)
Grade	
1	4 (10.5)
2	11 (28.9)
3	4 (10.5)
Undefined	19 (50)
ECOG PS <sup>a</sup>	
0–1	26 (68.4)
2	12 (31.6)

<sup>a</sup> Eastern Cooperative Oncology Group performance status.

**Table 2**  
Parameters affecting survival (univariate analysis).

	Median OS <sup>a</sup> (months)	P value
Age		0.528
$\leq 60$	32.7	
$> 60$	17.6	
Gender		0.439
Male	17.6	
Female	46.2	
ECOG PS <sup>b</sup>		0.245
0–1	226	
$> 1$	189	
Stage		0.111
Locally advanced	214	
Metastatic	142	
Grade		0.172
1	342	
2	462	
3	189	
SUVmax <sup>c</sup>		<b>0.019</b>
$\leq 11$	327	
$> 11$	165	

<sup>a</sup> Overall survival.

<sup>b</sup> Eastern Cooperative Oncology Group performance status.

<sup>c</sup> Standardized uptake value.

Download English Version:

<https://daneshyari.com/en/article/1084014>

Download Persian Version:

<https://daneshyari.com/article/1084014>

[Daneshyari.com](https://daneshyari.com)